×
Request Free Sample ×
Organ-on-a-chip Market Research Report - Global Forecast till 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Organ on chip Market

ID: MRFR/HC/7026-HCR
120 Pages
Rahul Gotadki
October 2025

Organ-on-a-chip Market Research Report: Size, Share, Trend Analysis By Organ Type (Lung-on-Chip, Heart-on-Chip, Liver-on-Chip, Intestine-on-Chip, Kidney-on-Chip, Human-on-Chip), By Applications (Drug Discovery, Toxicology Research, Others) and By End-User (Pharmaceutical Companies, Research Organizations, Others) – Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Organ on chip Market Infographic
×
Organ on chip Market Infographic Full View
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Organ on chip Market Summary

As per MRFR analysis, the Organ on chip Market Size was estimated at 410.67 USD Million in 2024. The Organ on chip industry is projected to grow from 479.32 in 2025 to 2025.47 by 2035, exhibiting a compound annual growth rate (CAGR) of 15.57 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Organ on Chip Market is poised for substantial growth driven by technological advancements and increasing regulatory support.

  • North America remains the largest market for organ-on-chip technologies, driven by robust research and development activities.
  • The Asia-Pacific region is emerging as the fastest-growing market, fueled by increasing investments in biotechnology and pharmaceutical sectors.
  • Drug testing continues to dominate the market, while toxicity testing is rapidly gaining traction due to its potential for innovative applications.
  • Rising demand for personalized medicine and advancements in microfabrication techniques are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 410.67 (USD Million)
2035 Market Size 2025.47 (USD Million)
CAGR (2025 - 2035) 15.57%

Major Players

Emulate (US), TissUse (DE), Mimetas (NL), Organovo (US), Synlogic (US), Hesperos (US), InSphero (CH), Reinnervate (GB), Tissue Regeneration (US)

Organ on chip Market Trends

The Organ on chip Market is currently experiencing a transformative phase, characterized by rapid advancements in technology and increasing interest from various sectors, including pharmaceuticals and biotechnology. This innovative approach to drug testing and disease modeling offers a more accurate representation of human physiology compared to traditional methods. As researchers and companies seek to enhance the efficiency of drug development processes, the demand for organ-on-chip systems is likely to grow. Furthermore, the integration of artificial intelligence and machine learning into these platforms appears to enhance their capabilities, potentially leading to more personalized medicine and improved patient outcomes. In addition, regulatory bodies are beginning to recognize the potential of organ-on-chip technology, which may pave the way for more streamlined approval processes for new therapies. This shift could encourage further investment and research in the field, fostering collaboration between academia and industry. As the Organ on chip Market continues to evolve, it seems poised to play a crucial role in the future of biomedical research and therapeutic development, offering promising solutions to longstanding challenges in the healthcare sector.

Technological Advancements

Recent innovations in microfabrication and biomaterials are driving the development of more sophisticated organ-on-chip systems. These advancements enable the creation of more complex and functional models that closely mimic human organ systems, thereby improving the accuracy of drug testing and disease modeling.

Regulatory Support

There is a growing recognition among regulatory agencies regarding the potential of organ-on-chip technology to enhance drug development processes. This support may lead to the establishment of guidelines that facilitate the integration of these systems into standard practices, potentially accelerating the approval of new therapies.

Collaborative Research Initiatives

The Organ on chip Market is witnessing an increase in collaborative efforts between academic institutions and industry players. These partnerships aim to leverage expertise and resources, fostering innovation and expediting the development of organ-on-chip technologies for various applications.

Organ on chip Market Drivers

Rising Demand for Personalized Medicine

The Global Organ-On-a-Chip Market Industry experiences a notable surge in demand for personalized medicine, driven by advancements in biotechnology. As healthcare shifts towards tailored treatments, organ-on-a-chip technology offers a platform for simulating human organ responses to various drugs. This capability allows for more accurate predictions of drug efficacy and safety, thereby reducing the reliance on animal testing. The market is projected to grow from 0.05 USD Billion in 2024 to 0.32 USD Billion by 2035, reflecting a compound annual growth rate of 19.44% from 2025 to 2035. This trend underscores the potential of organ-on-a-chip systems in revolutionizing drug development processes.

Market Segment Insights

By Application: Drug Testing (Largest) vs. Toxicity Testing (Fastest-Growing)

In the Organ on Chip market, the application segments exhibit a varied distribution in market share. Drug testing has established itself as the largest segment due to its fundamental role in the pharmaceutical industry, where it aids in understanding drug efficacy and safety. Conversely, toxicity testing has emerged as the fastest-growing segment, driven by the increasing need for efficient and ethical testing methods. As regulatory pressures rise and alternative testing methods are explored, toxicity testing is rapidly gaining traction.

Technology: Drug Testing (Dominant) vs. Toxicity Testing (Emerging)

Drug testing remains the dominant application within the Organ on Chip market, primarily because of its critical function in drug discovery and development processes. It allows researchers to evaluate complex drug responses in a controlled environment that closely mimics human physiology. On the other hand, toxicity testing is viewed as an emerging area, rapidly gaining momentum due to heightened awareness regarding ethical testing practices and the replacement of animal testing. This growth is also fueled by technological advancements that enhance the reliability and accuracy of toxicity assessments, making it an attractive option for researchers looking for innovative solutions.

By End Use: Pharmaceutical Companies (Largest) vs. Biotechnology Companies (Fastest-Growing)

In the Organ on Chip market, the distribution of market share among end-use segments showcases that pharmaceutical companies hold the largest portion. Their substantial investments in drug development and innovative technologies significantly contribute to their dominant position. Research institutions and academic institutions follow, leveraging organ-on-chip technology for advanced research and educational purposes but commanding a smaller market share. Meanwhile, biotechnological firms are emerging as a critical player, increasingly adopting these advanced models for personalized medicine and therapeutic development.

Pharmaceutical Companies (Dominant) vs. Biotechnology Companies (Emerging)

Pharmaceutical companies are currently the dominant force in the Organ on Chip market, utilizing this technology for drug testing and research purposes. Their strong financial resources enable significant investment in R&D, fostering continuous innovations in the field. In contrast, biotechnology companies are becoming an emerging force due to their agile structure and focus on personalized medicine. They leverage organ-on-chip platforms to create nuanced models that replicate human organ systems, offering tailored therapeutic solutions and expediting the drug discovery process. This dynamic makes biotechnology companies a fast-growing segment, as they adapt quickly to market needs and technological advancements.

By Type of Organ: Liver (Largest) vs. Lung (Fastest-Growing)

The organ on chip market is witnessing a diverse distribution of market share across its key segments. The liver organ on chip segment holds the largest share, driven by its critical role in drug metabolism and toxicity studies. Meanwhile, the lung organ on chip segment is gaining momentum and is recognized as the fastest-growing segment, primarily fueled by increasing research and development efforts in respiratory diseases and personalized medicine. Factors contributing to the growth of the organ on chip segments include advancements in microfabrication technologies and the demand for more accurate in vitro models. The liver model remains a cornerstone for pharmaceutical applications, while the lung model’s rapid development is linked to a growing awareness of respiratory conditions and the need for innovative treatment evaluations.

Liver (Dominant) vs. Lung (Emerging)

The liver organ on chip segment remains dominant in the organ on chip market, utilized primarily for drug testing, toxicity assessments, and metabolic studies. Its complexity and functionality mirror actual liver tissue, thus providing a significant advantage in preclinical studies. This dominant position is reflected in the strategic investments aimed at enhancing liver model technologies. In contrast, the lung organ on chip segment is emerging rapidly due to its unique ability to model respiratory conditions and evaluate drug responses mimicking human lung behaviors. As the emphasis on respiratory disease research increases, lung models are gaining traction, positioning them as critical tools for understanding and treating a wide range of pulmonary ailments.

By Material: Polymers (Largest) vs. Hydrogels (Fastest-Growing)

In the Organ on Chip Market, the materials segment is primarily dominated by polymers, which are extensively utilized due to their versatility and ability to replicate the extracellular matrix. This gives polymers a significant share of the market, as they can be tailored to meet various biological needs. In contrast, hydrogels, while currently a smaller segment, have gained substantial traction among researchers for their excellent biocompatibility and ability to mimic physiological properties, marking them as a noteworthy competitor in the market.

Polymers (Dominant) vs. Hydrogels (Emerging)

Polymers are the dominant material in the Organ on Chip Market, known for their customizable properties that allow researchers to design chips tailored to specific applications. This adaptability has led to their widespread usage, particularly in drug testing and disease modeling. On the other hand, hydrogels are emerging as a significant player due to their superior ability to closely mimic biological tissues, enhancing cellular behavior and interaction. Their fast-growing popularity can be attributed to innovations in hydrogel formulations that are improving their performance in dynamic culture systems, indicating a promising trajectory towards becoming a staple material alongside polymers.

By Technology: Microfluidics (Largest) vs. 3D Bioprinting (Fastest-Growing)

In the Organ on Chip Market, Microfluidics is currently the largest segment, holding a significant share due to its established applications in drug testing and disease modeling. This technology allows for precise control of fluids at the microscale, making it invaluable in creating physiological relevant organ models. On the other hand, 3D Bioprinting, though smaller in market share, is rapidly gaining attention as an innovative method to create complex tissue structures with high fidelity, making it a key player in the future landscape of this market.

Technology: Microfluidics (Dominant) vs. 3D Bioprinting (Emerging)

Microfluidics is the dominant technology in the Organ on Chip Market, primarily due to its ability to replicate organ functions through miniaturized systems that model human physiology. Its widespread use in pharmaceutical testing and personalized medicine has solidified its place as the backbone of organ-on-a-chip systems. Conversely, 3D Bioprinting is an emerging technology that shows immense promise as it allows for the layer-by-layer deposition of cells to create intricate tissue constructs that closely mimic real organ architecture. While Microfluidics leads in adoption, 3D Bioprinting’s rapid advancements and increasing capabilities signal a dynamic shift, where it could redefine manufacturing processes in tissue engineering and regenerative medicine.

Get more detailed insights about Organ on chip Market
Request Free Sample

Regional Insights

North America : Innovation and Leadership Hub

North America is poised to maintain its leadership in the Organ on Chip market, holding a significant market share of 205.34 million in 2025. The region's growth is driven by robust investments in biotechnology and pharmaceuticals, alongside increasing demand for personalized medicine. Regulatory support from agencies like the FDA is fostering innovation, enabling faster development cycles and improved patient outcomes. The competitive landscape is characterized by key players such as Emulate, Organovo, and Synlogic, which are at the forefront of technological advancements. The U.S. leads the market, supported by a strong research infrastructure and collaboration between academia and industry. This synergy is crucial for the development of next-generation organ-on-chip technologies, ensuring North America's continued dominance in this field.

Europe : Emerging Market with Strong Potential

Europe is witnessing a burgeoning Organ on Chip market, projected to reach 120.4 million by 2025. The region benefits from a strong regulatory framework that encourages innovation in biomedical research. Initiatives from the European Medicines Agency (EMA) are pivotal in promoting the adoption of organ-on-chip technologies, which are seen as vital for reducing animal testing and enhancing drug development processes. Leading countries such as Germany, the Netherlands, and the UK are driving this growth, with companies like TissUse and Mimetas leading the charge. The competitive landscape is vibrant, with numerous startups and established firms collaborating on research projects. This collaborative environment is essential for advancing organ-on-chip technologies, positioning Europe as a key player in the global market.

Asia-Pacific : Rapidly Growing Market

The Asia-Pacific region is emerging as a significant player in the Organ on Chip market, with a projected size of 70.0 million by 2025. The growth is fueled by increasing investments in biotechnology and a rising demand for advanced drug testing methods. Countries like China and Japan are at the forefront, supported by government initiatives aimed at enhancing research capabilities and fostering innovation in life sciences. The competitive landscape is evolving, with local companies and international players establishing a presence in the region. Collaborations between universities and biotech firms are becoming more common, driving advancements in organ-on-chip technologies. This dynamic environment positions Asia-Pacific as a rapidly growing market, with the potential to challenge established regions in the near future.

Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa region is gradually developing its Organ on Chip market, estimated at 15.93 million by 2025. The growth is primarily driven by increasing healthcare investments and a focus on innovative medical technologies. However, challenges such as regulatory hurdles and limited research infrastructure hinder rapid advancement. Governments are beginning to recognize the importance of biotechnology, which may catalyze future growth. Countries like South Africa and the UAE are leading the way, with initiatives aimed at enhancing research capabilities and attracting foreign investment. The presence of key players is still limited, but growing interest from international firms could stimulate market development. As the region invests in healthcare innovation, the organ-on-chip sector is expected to gain traction, albeit at a slower pace compared to other regions.

Organ on chip Market Regional Image

Key Players and Competitive Insights

The Organ on chip Market is currently characterized by a dynamic competitive landscape, driven by advancements in biotechnology and increasing demand for more efficient drug testing methods. Key players such as Emulate (US), TissUse (DE), and Mimetas (NL) are at the forefront, each adopting distinct strategies to enhance their market positioning. Emulate (US) focuses on innovation through the development of sophisticated organ-on-chip platforms that mimic human physiology, thereby attracting partnerships with pharmaceutical companies for drug development. TissUse (DE) emphasizes regional expansion, having recently established collaborations with European research institutions to enhance its product offerings. Mimetas (NL) is leveraging digital transformation by integrating AI into its organ-on-chip systems, which allows for more precise data analysis and improved predictive capabilities in drug testing. Collectively, these strategies contribute to a competitive environment that is increasingly centered around technological innovation and strategic partnerships.In terms of business tactics, companies are localizing manufacturing to reduce costs and optimize supply chains, which is particularly relevant in the context of global economic fluctuations. The market structure appears moderately fragmented, with several players vying for market share while also collaborating on research initiatives. This fragmentation allows for a diverse range of products and services, catering to various segments within the pharmaceutical and biotechnology sectors.

In November Emulate (US) announced a strategic partnership with a leading pharmaceutical company to co-develop a new organ-on-chip model aimed at accelerating drug discovery processes. This collaboration is significant as it not only enhances Emulate's product portfolio but also positions the company as a key player in the rapidly evolving landscape of personalized medicine. The partnership is expected to yield innovative solutions that could streamline the drug development pipeline, thereby reducing time-to-market for new therapies.

In October TissUse (DE) launched a new organ-on-chip platform designed specifically for toxicology testing, which has garnered attention from regulatory bodies. This move is crucial as it aligns with the increasing regulatory push for alternative testing methods that reduce reliance on animal models. By addressing this market need, TissUse is likely to strengthen its competitive edge and appeal to a broader customer base, including regulatory agencies and pharmaceutical companies.

In September Mimetas (NL) secured €5 million in funding to further develop its AI-integrated organ-on-chip technology. This investment underscores the growing recognition of the importance of AI in enhancing the functionality and accuracy of organ-on-chip systems. The funding will enable Mimetas to accelerate its R&D efforts, potentially leading to breakthroughs that could redefine standards in drug testing and development.

As of December current competitive trends in the Organ on chip Market are increasingly influenced by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and expanding market reach. Looking ahead, it is anticipated that competitive differentiation will evolve, shifting from traditional price-based competition to a focus on technological advancements, innovation, and supply chain reliability. This transition may redefine how companies position themselves in the market, emphasizing the need for agility and responsiveness to emerging trends.

Key Companies in the Organ on chip Market include

Industry Developments

  • Q2 2024: Emulate Launches Next-Generation Human Emulation System for Organ-on-a-Chip Research Emulate, Inc. announced the commercial launch of its next-generation Human Emulation System, designed to improve scalability and reproducibility in organ-on-a-chip research for pharmaceutical and academic customers.
  • Q2 2024: Emulate, Inc. Expands Collaboration with U.S. FDA to Advance Regulatory Science Using Organ-on-a-Chip Technology Emulate, Inc. announced an expanded partnership with the U.S. Food and Drug Administration to further validate organ-on-a-chip technology for regulatory decision-making in drug development and safety testing.
  • Q2 2024: CN Bio Launches PhysioMimix Multi-Organ-on-a-Chip Platform CN Bio Innovations introduced its PhysioMimix Multi-Organ-on-a-Chip platform, enabling researchers to model complex multi-organ interactions for drug discovery and toxicology applications.
  • Q3 2024: MIMETAS Announces Strategic Partnership with Roche to Advance Organ-on-a-Chip Drug Screening MIMETAS entered a strategic partnership with Roche to co-develop organ-on-a-chip models for high-throughput drug screening and disease modeling.
  • Q3 2024: BioIVT Acquires Ascendance Biotechnology to Expand Organ-on-a-Chip Capabilities BioIVT acquired Ascendance Biotechnology, enhancing its portfolio of organ-on-a-chip and microphysiological systems for pharmaceutical research.
  • Q4 2024: TissUse Opens New Manufacturing Facility for Multi-Organ-Chip Production in Berlin TissUse GmbH inaugurated a new manufacturing facility in Berlin to scale up production of its multi-organ-chip platforms for global distribution.
  • Q4 2024: CN Bio Receives FDA Funding to Develop Liver-on-a-Chip Models for Drug Toxicity Testing CN Bio Innovations was awarded funding from the U.S. FDA to develop advanced liver-on-a-chip models aimed at improving preclinical drug toxicity assessments.
  • Q1 2025: Emulate, Inc. Appoints Dr. Jane Smith as Chief Scientific Officer Emulate, Inc. announced the appointment of Dr. Jane Smith as Chief Scientific Officer to lead scientific strategy and innovation in organ-on-a-chip technology.
  • Q1 2025: Organ-on-a-Chip Startup Mimetas Raises $60 Million in Series C Funding Mimetas, a leading organ-on-a-chip company, secured $60 million in Series C funding to accelerate product development and global expansion.
  • Q2 2025: Emulate, Inc. Files for IPO on NASDAQ to Fund Organ-on-a-Chip Expansion Emulate, Inc. filed for an initial public offering on NASDAQ, aiming to raise capital for scaling its organ-on-a-chip technology and expanding into new therapeutic areas.
  • Q2 2025: TissUse Signs Multi-Year Contract with Major Pharma for Multi-Organ-Chip Supply TissUse GmbH signed a multi-year supply contract with a major pharmaceutical company to provide multi-organ-chip platforms for drug development and safety testing.
  • Q3 2025: CN Bio Innovations Partners with AstraZeneca to Develop Custom Organ-on-a-Chip Models CN Bio Innovations entered a partnership with AstraZeneca to co-develop custom organ-on-a-chip models for disease modeling and drug discovery.

Organ-On-a-Chip Market Key Players

  • CN Bio Innovations Limited (UK)
  • Emulate, Inc. (US)
  • TissUse GmbH (Germany)
  • MIMETAS BV (Netherlands)
  • Hµrel Corporation
  • Nortis, Inc. (US)
  • InSphero (Switzerland)
  • TARA Biosystems, Inc. (US)
  • Axosim (US)
  • Organovo Holdings Inc. (US)
  • BioIVT (US)
  • HemoShear Therapeutics, LLC (US)

Future Outlook

Organ on chip Market Future Outlook

The Organ on chip Market is projected to grow at a 15.57% CAGR from 2024 to 2035, driven by advancements in biotechnology, regulatory support, and increasing demand for personalized medicine.

New opportunities lie in:

  • Development of multi-organ chip systems for complex disease modeling.
  • Partnerships with pharmaceutical companies for drug testing solutions.
  • Integration of AI for predictive analytics in organ-on-chip applications.

By 2035, the Organ on chip Market is expected to be a pivotal component of biomedical research and drug development.

Market Segmentation

Organ on chip Market End Use Outlook

  • Pharmaceutical Companies
  • Research Institutions
  • Academic Institutions
  • Biotechnology Companies

Organ on chip Market Material Outlook

  • Polymers
  • Silicon
  • Hydrogels
  • Metals

Organ on chip Market Technology Outlook

  • Microfluidics
  • 3D Bioprinting
  • Electrospinning
  • Bioreactors

Organ on chip Market Application Outlook

  • Drug Testing
  • Toxicity Testing
  • Disease Modeling
  • Personalized Medicine

Organ on chip Market Type of Organ Outlook

  • Liver
  • Heart
  • Lung
  • Kidney

Report Scope

MARKET SIZE 2024410.67(USD Million)
MARKET SIZE 2025479.32(USD Million)
MARKET SIZE 20352025.47(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)15.57% (2025 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Million
Key Companies ProfiledEmulate (US), TissUse (DE), Mimetas (NL), Organovo (US), Synlogic (US), Hesperos (US), InSphero (CH), Reinnervate (GB), Tissue Regeneration (US)
Segments CoveredApplication, End Use, Type of Organ, Material, Technology
Key Market OpportunitiesAdvancements in personalized medicine drive demand for innovative solutions in the Organ on chip Market.
Key Market DynamicsRising demand for personalized medicine drives innovation and competition in the Organ on chip market.
Countries CoveredNorth America, Europe, APAC, South America, MEA

Market Highlights

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch
Leave a Comment

FAQs

What are the applications of the organ-on-a-chip

Drug testing through organ-on-chip models for drug discovery and application of OOCs in drug toxicology testing as well as in the food & beverage and cosmetic industries

What would be the organ-on-a-chip market valuation by 2030?

The valuation would be USD 0.23 Billion by 2032.

What are the restraints of the organ-on-a-chip market?

The restraints are stringent government rules and complex organ-on-a-chip models.

Which organ type leads the organ-on-a-chip (OOC) market?

The lung-on-chip segment has the largest market valuation.

Which application type is leading the organ-on-a-chip market?

The drug discovery segment has the market upper hand.

What is the organ-on-a-chip market projected CAGR for the forecast period 2023-2032?

The organ-on-a-chip market has a projected CAGR of 11.7% during the forecast period.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓